Purevax RC
vaccine against feline viral rhinotracheitis and feline calicivirosis
Table of contents
Overview
This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This document cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Purevax RC
|
Agency product number |
EMEA/V/C/000091
|
Active substance |
|
International non-proprietary name (INN) or common name |
vaccine against feline viral rhinotracheitis and feline calicivirosis
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI06AH
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
14
|
Date of issue of marketing authorisation valid throughout the European Union |
23/02/2005
|
Contact address |
Product information
14/10/2020 Purevax RC - EMEA/V/C/000091 - WS/1732/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Immunologicals for felidae
Therapeutic indication
Active immunisation of cats aged eight weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs;
- against calicivirus infection to reduce clinical signs and excretion.
Onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis and calicivirus components.
The duration of immunity is three years after the last re-vaccination.